Natera, Inc. $NTRA Shares Bought by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. grew its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 5,965.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 343,768 shares of the medical research company’s stock after acquiring an additional 338,100 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.25% of Natera worth $78,754,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of NTRA. JPMorgan Chase & Co. lifted its position in shares of Natera by 9.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after acquiring an additional 1,003,129 shares during the period. Franklin Resources Inc. lifted its position in shares of Natera by 37.5% during the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after acquiring an additional 727,366 shares during the period. AQR Capital Management LLC lifted its position in shares of Natera by 39.0% during the 3rd quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock valued at $386,338,000 after acquiring an additional 673,315 shares during the period. Millennium Management LLC raised its position in shares of Natera by 215.7% during the 3rd quarter. Millennium Management LLC now owns 527,942 shares of the medical research company’s stock worth $84,983,000 after purchasing an additional 360,733 shares during the last quarter. Finally, American Century Companies Inc. raised its position in shares of Natera by 39.5% during the 3rd quarter. American Century Companies Inc. now owns 843,427 shares of the medical research company’s stock worth $135,766,000 after purchasing an additional 238,679 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of NTRA opened at $193.03 on Monday. The stock has a fifty day moving average of $204.07 and a two-hundred day moving average of $210.66. The company has a market capitalization of $27.36 billion, a PE ratio of -126.16 and a beta of 1.68. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The company had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. During the same period in the previous year, the company earned ($0.41) EPS. As a group, equities research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity at Natera

In other news, insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $202.30, for a total transaction of $606,900.00. Following the completion of the sale, the insider directly owned 147,882 shares of the company’s stock, valued at $29,916,528.60. The trade was a 1.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 5,623 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $204.13, for a total transaction of $1,147,822.99. Following the sale, the chief executive officer directly owned 156,607 shares of the company’s stock, valued at $31,968,186.91. This represents a 3.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 314,545 shares of company stock valued at $73,141,185 over the last quarter. 5.63% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NTRA. JPMorgan Chase & Co. lifted their price objective on Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Wells Fargo & Company boosted their price target on Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. TD Cowen reiterated a “buy” rating on shares of Natera in a report on Wednesday, January 7th. Finally, Canaccord Genuity Group reiterated a “buy” rating on shares of Natera in a report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.47.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.